Increased Global, Subcutaneous Inflammation in Psoriasis

Share this content:
Increased Global, Subcutaneous Inflammation in Psoriasis
Increased Global, Subcutaneous Inflammation in Psoriasis

THURSDAY, Nov. 3, 2016 (HealthDay News) -- Psoriasis patients have increased global arterial inflammation and subcutaneous inflammation, according to a study published online Oct. 27 in the British Journal of Dermatology.

Kasper F. Hjuler, M.D., from the Aarhus University Hospital in Denmark, and colleagues examined signs of vascular inflammation in 12 untreated patients with moderate-to-severe psoriasis compared with 23 retrospectively matched controls assessed using 18F-fluorodeoxyglucose (FDG) positron emission tomography computed tomography. Aortic maximal standardized uptake values (SUVmax) and target-to-background ratio (TBRmax) of the whole vessel and aortic segments were used to measure vascular inflammation.

The researchers found that psoriasis patients had increased arterial inflammation compared with controls (mean whole vessel TBRmax, 2.46 versus 2.09; P = 0.005) and had increased average normalized FDG uptake based on conservative 10-pixel cut-off SUVmax values (mean TBRmax-10pixels, 2.13 versus 1.92; P = 0.03). Higher FDG uptake values were seen for all aortic segments except the ascending aorta in psoriasis patients. Compared with controls, psoriasis patients had increased subcutaneous adipose tissue FDG uptake (mean TBRmax, 0.49 versus 0.31; P = 0.002; mean TBRmax-10pixels, 0.39 versus 0.28; P = 0.01).

"Both global arterial inflammation and subcutaneous inflammation were significantly increased in patients with moderate-to-severe psoriasis compared with controls," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »